Drugs / Neumifil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05093530 | Oct 2021 → Apr 2022 | viral respiratory tract infection | Pneumagen Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05507567 | Aug 2022 → May 2023 | influenza | Pneumagen Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neumifil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05093530 ↗ |
| Route | Intranasal | “Neumifil will be administered intranasally using an Aptar delivery system.” NCT05093530 ↗ |